

Ig-PLP1

Ig-PLP-LR




Fig 2A.




Fig. 2B




Figure 2

[³H]-Thymidine incorporation (cpm x 10⁻³)





Figure 3




Figure 5

% Control [^3H]-Thymidine Incorporation

120
100
80
60
40
20
0

a

Fig 5A

120
100
80
60
40
20
0

b

Fig 5B


120
100
80
60
40
20
0

c

Fig. 5C

Inhibitor (μM)

—■— Ig-PLP-LR
—◆— Ig-W
—●— PLP-LR
—▲— PLP2






Figure 6




Fig. 7A




Fig. 7B

■ PLP1
▨ PLP2

Figure 7

Fig 8b

Fig 8a

● Ig-PLP1 + Ig- W
◆ Ig-PLP1 + Ig- PLP-LR




Figure 8




Fig. 9B




FIGURE 10




FIGURE 11




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 19




FIGURE 20




FIGURE 21